Page last updated: 2024-10-29

avapro and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

avapro has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Schoepf, AM1
Salcher, S1
Obexer, P1
Gust, R1

Other Studies

1 other study available for avapro and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARĪ³ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
    European journal of medicinal chemistry, 2020, Jun-01, Volume: 195

    Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistan

2020